Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They were able to justify the further exploration of a possibility. That was over a year ago. Let us know when you have some meaningful information.
Why have six of the eight scientists who were working on this only 2 years back, at Fort Wayne Metals, were from CSM ?
https://www.sciencedirect.com/science/article/abs/pii/S0167577X21013288#:~:text=Continuous%20Equal%20Channel%20Angular%20Pressing%20(C%2DECAP)%20is%20a,mechanical%20properties%20of%20many%20alloys.
Loaded up? Volume traded at $.006 was tiny.
Heavily shorted? Would love to see a link to information to back up that asinine claim.
Loaded up at .006. Nice 33%gain. Very HEAVILY SHORTED!!!!
Lots of discussion like this one regarding U.S. power grid:
Whoa, 5 cents. Those low shares just keep going lower and lower. Someone better call marvin lmao.
Neither this new strategy nor all the links to proulx promo's are helping the stock prices very much. mhtx .075, ibx still below 3 cents and creeping back down.
What happened to the metals deal?
How will mhtx and ibx fund operations going forward? Both are almost out of cash. Got any links to address those questions?
Those low shares just keep going lower and lower. Buy low and watch as price goes lower not a good investment strategy.
Looks like manny and marv have finally sucked all the life out of mhtx (and all the cash). They don't even bother to put out a fluffed up annual update anymore. And what has become of that metals deal? lock these guys up.
This new direction is a far cry from the promises from manny and marv. To see how disgusting these guys really are, read this update from 2014:
http://mhtx.com/news-and-media/press-releases/mhtx-issues-report-to-shareholders-pushing-the-limits-of-cancer-detection/
Almost 10 years ago they were bragging about taking the technology from bench to bedside. Even hired a consultant to accelerate the FDA approval process. Now it is clear that there never was a human instrument, not 10 years ago, not today. Penny stock con games, they never end.
Same old Proulx, good talker but he has squandered this opportunity that was handed to him.
The problem I have with this change of its core business is not the idea of having a non-invasive way of diagnosing cancer in the lymph nodes, this is a wonderful achievement, if it is proven out with more than just a few patients in a seemingly difficult study now going on for three years?
Proulx fails to mention the risks, which are many, starting with the competiton with more $$$ who can quickly capitalize on this achievement with more resources and very skilled management. He does add this in the IBX website, but I see this as more cover his bu-- after all how many investors actually look at the site on a daily basis, when you have the magical oz behind the curtain, pumping out videos.
What are the main risks associated with this shift?
We will face the same risks associated with new product entry in established and entrenched markets where low-cost ultrasound is ubiquitous despite performance limitations. However, we believe introduction for use with MRI will reduce those risks compared to introducing a new technology. We are not aware of other players trying to address the unmet medical need that we are by molecular imaging and hence expect to benefit from being the first mover and potentially obtain regulatory exclusivity in certain jurisdictions if approved first.
Same risks as new products
Not aware of competitors, which means there is nothing proprietary that IBX has that others can't quickly copy.
So how many years now and millions and millions spent on a technology that he couldn't make work and now he realizes that the non-proprietary nanoparticles work with MRI. I hope I am dead wrong and the SP flies to the moon, but without a partner like Siemens or some big name, this will be another nano particle company, not what I invested $$ into.
Anyone listen to proulx's "fireside chat" last night? If not, you should catch the replay. Don't be surprised or confused if you hear nothing about finances, just watch the share price to learn how much proulx's latest promo video is really worth.
The Future of Magnetic Relaxometry (MRX)
The Company plans to continue to develop the proprietary detection technology, known as the magnetic
relaxometry (MRX) in collaboration with academic and industry partners, focusing on a new generation of
small magnetic sensors that could enable the use of magnetic relaxometry, (Magsense), in the doctor’s office.
In the future MRX could be a game-changing instrument that would allow non-invasive cancer diagnosis at
the first point of care, e.g. at the urologist or OB/Gyn or general practitioner.
Do you think the world will ever see a commercialized Magsense human instrument?
From the Announcements Highlights :
Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance Imaging (MRI).
Further in Paragraph 5 :
The confirmation by the panel of the Company’s assessment that cancer detection can be achieved when using the MagSense® imaging agent with MRI has significant implications for the Company.
Refer Pge 2 Paragraph 1 :
“We will continue to refine our proprietary relaxometry technology but can now confidently shift our resources to developing our nanoparticles for use with MRI, a ubiquitous imaging modality used in hospitals and radiology clinics throughout the world. We believe this will be more attractive for strategic partners and more likely for us to achieve commercial success sooner.” Since all MagSense® targeted imaging agents use the same underlying magnetic nanoparticle technology, the Company now plans to prioritize the development of its MagSense® nanoparticle technology for use with mainstream clinical MRI scanners. (Later reference : there are 30,000 clinical grade MRI scanners globally)
IMO this good news announcement is the start of an SP turnaround as the market becomes aware of our potential. Further patient data will continue to build our support as it becomes available. Our commercialisation strategy is being revealed and Siemens involvement may be the next good news release.
Interesting development, let's see how things shake out this week. Looks like good news for nanoparticles, but the end of the Magsense human instrument dream as it was described from marvin, manny and proulx for a decade. How this new approach translates across over 1 billion shares and cash running out is the question.
But at least now everyone can agree that, in spite of numerous claims to the contrary, completion of the the design and development of a human instrument hasn't happened and is a long, long way off (if it ever happens at all).
IBX, some great news from an independent blinded review by a panel of expert breast cancer radiologists which has corroborated previously reported positive findings for the company’s MagSense diagnostic tech.
The company says that the radiologists confirmed that the “MagSense HER2 imaging agent produces a change in image contrast and that the contrast in nodes highly suspicious for tumour is distinctly different from the MR image contrast seen in non-involved nodes”.
“The outcome of the independent review is welcome news, indeed,” Imagion Biosystems CEO Bob Proulx said.
“We now have a clear indication that our MagSense magnetic nanoparticle technology could work with the existing medical imaging infrastructure to provide the clinical benefit to breast cancer patients we have been aiming for.
“This takes a lot of the technical risk out of the future and will significantly facilitate market entry by eliminating the need to design, make, sell, and support new machinery.”
It appears that IBX's Magsense is taking a quicker financial road to success by focusing on collaborating with powerhouses like , maybe Siemens MRI, while still continuing work on their own MRX technology independently. We'll know better after their presentation tomorrow...
https://imagionbiosystems.com/news/priority-path-to-market-for-magsense-technology/
As everyone (at least the four of us LOL) knows that I have been harsh on Proulx, and I understand shareholders discontent with the present stock value and the necessity for extra financing, but it's vital to retain the outlook for the far-reaching ramifications of this innovation which I still believe in.
I guess I am feeling rather optimistic these days despite all these silly videos..Fabricating a life-saving contraption necessitates effort and investment, and while the primary 20 cent IPO holders may not immediately see monetary profits, it's essential to think about the bigger picture and the achievable positive effect this technology could have on individuals' lives.
The conclusion of the initial study is a critical turning point and will bring Imagion closer to achieving its aspirations. For now, let's persist in staying optimistic and positive about the future of this firm and its possible influence on humanity. It's not always about money.
Haven't heard a peep about the metals deal (aka manny and marv's latest meal ticket) for quite a while. Correct me if I am wrong, but I think those cash payments are about done. Why no updates from m&m? Running out of cash and price below a penny - maybe the boys have milked this one dry?
Any of you loyal believers spoken to manny or marv recently? Or are they no longer accepting your calls?
Another proulx promo, with not a word about the poor shareholders who paid 20 cents for this now 2 cent stock. Not a word about the need to raise cash or anything he will do to increase shareholder value (fyi, diluting at 2 cents or less to raise $millions is not going to help).
He did reinforce the message that if/when this 1st study is completed there will be a need for a much larger study (fyi, much larger cash requirements). Someday this might be a life saving instrument, but it won't save the financial life on the initial 20 cent ipo holders.
I can't seem to get this Interview to appear on here, but simply copy and view this from 2 days ago...
executive interviews/robert proulx of imagion biosystems
All those low mhtx shares lol. What to do with them with a bid of 8 cents?
Buy low and watch it go lower - not a good investing strategy.
Anyone have an estimate on when ibx will run out of cash? Sometime in 2nd quarter, yes?
A revised patent issued to IBX...
https://patents.justia.com/assignee/imagion-biosystems-inc
If ibx is a legitimate company, proulx should get fired soon. His performance has been despicable. If he remains as ceo, then it is clear this is just another manny and marv type of production. mhtx now below a penny, so good luck with that one too.
Good news coming? Like how much dilution it will take to continue to pay these people? Or maybe, after over 2 years, proulx has managed to find 15 people willing to participate in his disastrous study?
IBX now has 25 workers in San Diego. Did some research on which 10 have been added within last 6 months, 9 within last 1 to 2 years, 3 within 2 to 5 years and 3 since the founding of IBX. Some good news has to be coming.
Kudos for a realistic, no bullshit summary of 2022. Sadly, ibx is just about out of cash and has made very little progress toward commercializing the magsense technology. 2023 will see fund raising at share price near a penny imo and the massive dilution that goes along with it. No promo videos, interviews or luxury living by proulx will change that.
But an even more painful possibility needs to be faced. After more than a decade and many, many millions of dollars, the day of anything meaningful coming out of the ibx lab is still light years away. Why? Either the acquisition of the Flynn technology 12 years ago has been followed by a stream of the most incompetent and/or dishonest leadership imaginable OR the whole thing really just doesn't work.
Consider this p/r from April 2010:
Happy New Year indeed,
2022 has been a difficult year for IBX holders, with the value of their holdings dropping from 8 cents in January to 2.4 cents by December 30th. Despite market conditions, there was little recovery. Shareholders are calling for significant changes in the coming year, including increased communication and potentially a change in leadership. The current CEO Bob Proulx has been criticized as a contributing factor to the decline of the stock and overall, the drop in value has been a significant loss for investors, will the losses continuing.
IF the company wants to cash in on those options still out there, there needs to be some significant announcement, otherwise, things will get crazy as Bob tries to raise anything substantial at this present and dropping stock price.
Get your act together Bob or move out of the way.
Looks like ibx could break below 2 cents soon. How about more interviews and promo videos from proulx? Maybe one from inside his lake tahoe home would really get the stock moving. lmao.
Happy New Year to all those happy owners of ibx shares (now $.023 and heading towards a penny and massive dilution imo), and mhtx shares (now under a penny and nothing but silence from manny and marv - lock them up).
2023 looking like the year both companies run out of cash (or dilute even more). 2 year old ibx trial, still no human instrument. And that metals deal? Sad, sad joke. Will there be a shareholder update from manny and marv about all the great things that are right around the corner? And how many interviews and promo videos for proulx this year? Will the trial ever get fully enrolled? Will it ever be completed? And if so, how long and how much cash for the next, larger trial? Sounds like manny, marv and proulx should be on trial themselves.
Ask .009 and volume zero. Under a penny and still no one wants this garbage. I guess most people actually do read the financial filings. Sorry marv.
Whoa, picked up some Low shares.
Look @ the market, what can you buy, Tesla, apple - good luck .
MHTX -No where to go but UP .
And mhtx drops below a penny. ibx can't be far behind as cash is running out. If only proulx could enroll patients in ibx trial as fast as he pumps out videos and interviews.
New video with IBX progress Bob Proulx put out a few days ago.
https://themarketherald.com.au/imagion-biosystems-asxibx-reports-positive-first-magsense-breast-cancer-clinical-data-2022-12-08/
My post said "it took 2 years into the study to produce this interim result which includes 6 people".
Do you know how many patients are in the 2nd cohort?
Did you read about the need for further studies on a broader scale?
Do you understand latest financials show less than 2 quarters of cash remaining and this includes the $2.5 million tax credit?
While there may be hope for the technology someday, there is no doubt that cash is running out and probably massive dilution on the way. None of these links to articles, interviews, and promotions say otherwise and the share price confirms it.
By the way, why no mention of manny and marv metals deal as mhtx struggles to hold above a penny and they have once again burned all the easy upfront cash? Silence speaks volumes.
For those saying "only 6 patients"... Did you not read the announcement? The first cohort was 6 patients and the second cohort has already received consistent results with the first.
That is good news. But here is an interesting piece of the article and one of the reasons why the stock is heading toward a penny:
And from the collaboration agreement between PAB and IBX signed 6 months ago...
Dr. James Campbell, Patrys’ CEO and Managing Director. “The potential for our deoxymab antibodies to home in on a range of different cancer types due to their affinity for DNA is one of the properties that makes them so unique and opens up a range of different clinical applications for their use. We are very excited to be further leveraging the cancer-targeting ability of deoxymabs by partnering with Imagion and its innovative MagSense® imaging technology to potentially develop new ways to visualise and diagnose cancer. This is the first of multiple potential applications of our deoxymab platform, and while our focus is on advancing our novel cancer therapeutics to the clinic we are actively engaged in business development efforts for the broader platform to leverage theunique attributes of deoxymabs.”
From a recent email reply of James Campbell, (CEO to Patrys Limited)...
"As well as the DX1 advances, investors should keep an eye on DX3, and the fact that we are already working with other companies to explore delivery of different payloads. This could generate some non-dilutive cash for us as we push forward into the clinic"
That's an interesting thought. I wonder how proulx will go about raising the share price (please, not more interviews and promo videos lol). He has shown no ability to do so in recent years and has also demonstrated complete disdain for shareholder value as he has diluted to over 1 billion shares and has done placements at very low prices. Issuing another 1/2 billion shares or even another billion would not seem to concern him at all.
Hopefully a reverse split wasn't the method to be used to "raise the sp". Companies like ibx typically see the post-reverse split price quickly return to the pre-split level and dilution run wild. Unfortunaely, it looks like that would be the only thing that could get ibx back to the 20 cent ipo level.
The real question should be how long can Lake Tahoe proulx remain as ceo without delivering a completed trial and an actual plan to increase shareholder value. Amazing how those who post here refuse to hold his feet to the fire; hopefully ibx bod will soon. This has been a multi-year disaster for investors and, more important, a travesty for all who could have benefited from this technology over the last 10 years.
yes, Proulx has managed to muck it all up with that difficult trial.
yes, dilution is coming, probably before end of 2nd quarter.
no, I don't believe 2 cents is coming, he will need to raise the sp before the dilution.
"Those who have knowledge, don't predict. Those who predict, don't have knowledge"
Looking thru latest quarterly report from ibx (now I see why no one else mentioned it), looks like they have less than 2 quarters worth of cash left and still haven't fully enrolled the 2 year old trial. Icing on the piece of crap cake - expenses are expected to increase going forward. Anyone denying that Lake Tahoe proulx has totally screwed up the trial and is running shareholder value into the ground deserves a big piece of that cake. Big time dilution is on the way and it's going to happen with a share price close to a penny. But hey, he sure does a lot of interviews and there certainly are a lot of links being posted. That'll get you 2 cents/share, at least for a while.
This article, published in May, shows Marie Zhang of Imagion Biosystems, San Diego as an author. Hover over her name in the list of authors. https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.2c00167
Not the one I am searching for...but appreciate the effort.
Looking for the "Optimizing Magnetic Nanoparticles for MR Contrast" that they tweeted. They teased us without showing what the results showed.
Followers
|
84
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
9560
|
Created
|
11/30/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |